FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Pfizer | ADHD | FDA

What's Shire doing to support Vyvanse?

Tools

Are worries about Shire's Adderall successor justified? The Wall Street Journal Health Blog asked CEO-to-be Angus Russell (photo), who said that the company is hot on the sales trail in support of Vyvanse, which is already approved to treat ADHD in children and is up for FDA consideration for that use in adults. The company is hoping to market the med to adults by this summer, Russell said; though the FDA has said it would take action by April 28, he said, the agency hasn't even approved a new indication for an ADHD med without a round of questioning.

Meanwhile, Shire stock is down from its 52-week high last September as investors worry that doctors won't adopt Vyvanse fast enough to replace Adderall, which goes generic next year. And it's been bandied about as a takeover target for Pfizer. For Russell's view on that, you'll have to watch the video.

- see the Health Blog item
- watch the video

Related Articles:
Shire on lookout for acquisitions. Report
FDA hands out two key regulatory approvals. Report
Rumor Mill: AZ a possible Shire suitor. Report

More stories about FDA   Pfizer   ADHD  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 13 + 27?
To combat spam, please solve the math question above.